Список литературы

1. Семиглазов В.Ф., Семиглазов В.В., Дашян Г.А. Обоснование международных стандартов лечения операбельных форм рака молочной железы. Санкт-Петербург. 2009. 60 с.

2. American Cancer Society.

3. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet. 2009;374:2055.

4. Albain KS, Barlow WE, Shack S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncol. 2010;11:55-65.

5. Berry DA, Cirricincione C, Henderson 1С, et al. Estrogen-receptor status and outcomes of modem chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1668-1667.

6. Black D, Younger J, Martei Y, et al. Recurrence risk in Tla-b, node-negative, HER2 positive breast cancer. Breast Cancer Res Treat. 2006; 100(suррl 1; abstr 2037).

7. Cardoso F, Veer L, Rutgers E et al. Clinical application of the 70-gene profile: The MINDACT Trial. J Clin Oncol. 2008;26:729-735.

8. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697-6704.

9. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of her-2 overexpreasion/amplification in patients with small tumor size (pTla-b) and node-negative breast cancer. J Clin Oncol. 2009;27:5693-5699.

10. Cuzick J, Dowsett M. Wale С et al. Prognostic value of a combined ER, PgR Ki67, HER2 immunochemical (IHC4) score and comparison with the GHI recurrence score - results for TansATAC [abstract 74].

11. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: An overview of the randomised trials. Lancet. 2005;365:1687-1717.

12. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319-1329.

13. Goldstein L, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic risk factors. J Clin Oncol. 2008;25:4063-4171.

14. Gonzalez-Angulo AM, Litton .IK, Broglio KR, et al. High risk of recurrence for breast cancer patients with HER2-positive node negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700-5706.

15. Howell A, Gonzales-Angulo A, Burstein H. Adjuvant therapy for breast cancer: does stage matter in the era of tailored. ASCO Education book.-Chicago.-2010.-P.9-14.

16. Joensuu H, Kellokumpu-Lehtinen PL, Bono P. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-820.

17. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pTINOMO breast cancer: A nationwide population-based study. Clin Cancer Res. 2003;9:923-930.

18. McArthur III., Morris PG, Patil S, et al. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer study rationale (abstract 228). Proc Breast Symp. 2009.

19. Mook S, Schmidt MK, Viale G et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2009; 116: 295-302.

20. National Comprehensive Cancer Network. NCCN: Clinical practice guidelines in oncology 2010, www.nccn.org.

21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.

22. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Treatment of node-negative infra-centrimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol. 2009;27:(suppl; abstr 517).

23. Romond EH, Perez КЛ. Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-poeitive breast cancer. N Engl J Med. 2005;353:1673-1684.

24. Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC≥T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC≥TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract A-52]. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006.

25. Sotoriou C, Puztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.

26. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials J Clin Oncol. 2008;26:721-728.

27. Tovey SM, Brown S, Doughty JC, et al. Poor survival outcomes in HER2-poeitive breast cancer patients with low-grade, node-negative tumors. Br J Cancer. 2009;100:680-683.

28. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008;19:1090-1096.

29. Viani GA, Afonao SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer. 2007,7:153.

30. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.